<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02673138</url>
  </required_header>
  <id_info>
    <org_study_id>1508016333</org_study_id>
    <secondary_id>1K12DK094714-01</secondary_id>
    <nct_id>NCT02673138</nct_id>
  </id_info>
  <brief_title>Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion</brief_title>
  <official_title>Effect of Canagliflozin in T1DM After Interruption of Continuous Subcutaneous Insulin Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be an open-label, cross-over study as subjects will be studied under both&#xD;
      study conditions - suspension of subcutaneous insulin infusion via pump during treatment with&#xD;
      insulin alone (control) vs. suspension of subcutaneous insulin via pump during treatment with&#xD;
      insulin and canagliflozin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will consist of 4 visits: an enrollment/screening visit, a control visit with pump&#xD;
      suspension prior to treatment with canagliflozin, a visit with pump suspension while on&#xD;
      canagliflozin and an end of study visit. Each of the pump suspension visits will be&#xD;
      approximately 20-hour overnight admissions to the Hospital Research Unit (HRU).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin</measure>
    <time_frame>20 hours</time_frame>
    <description>The primary outcome measure for this study will be differences in plasma glucose levels following the interruption of basal subcutaneous infusion of insulin under the two study conditions; i.e., control study during treatment with insulin alone vs. experimental study during treatment with insulin plus canagliflozin or other SGLT2 inhibitor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal</measure>
    <time_frame>20 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion</measure>
    <time_frame>20 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion</measure>
    <time_frame>20 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Basal interruption</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Basal interruption with canagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>canagliflozin</intervention_name>
    <description>basal interruption with canagliflozin</description>
    <arm_group_label>Basal interruption with canagliflozin</arm_group_label>
    <other_name>Invokana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>basal interruption without canagliflozin</intervention_name>
    <description>basal interruption</description>
    <arm_group_label>Basal interruption</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-45 years&#xD;
&#xD;
          2. Clinical diagnosis of T1D (type 1 diabetes) (formal antibody and/or genetic testing&#xD;
             will not be required)&#xD;
&#xD;
          3. Duration of T1D ≥ 1 year&#xD;
&#xD;
          4. HbA1c ≤ 9 %&#xD;
&#xD;
          5. Treated with continuous subcutaneous insulin infusion (with or without adjunctive&#xD;
             treatment with a SGLT2 inhibitor) for at least 3 months&#xD;
&#xD;
          6. Body weight &gt; 40 kg&#xD;
&#xD;
          7. Be in good general health without other acute or chronic illness that in the judgment&#xD;
             of the investigator could interfere with the study or jeopardize subject safety&#xD;
&#xD;
          8. Normal hematocrit&#xD;
&#xD;
          9. Able to give consent&#xD;
&#xD;
         10. Female subjects of reproductive potential must be abstinent or consistently using&#xD;
             appropriate family planning methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Insulin resistant (defined as requiring &gt; 1.5 units/kg/day at time of study&#xD;
             enrollment)&#xD;
&#xD;
          2. Renal impairment, determined as eGFR &lt; 60 ml/minute/1.73m2&#xD;
&#xD;
               1. History of unstable or rapidly progressing renal disease&#xD;
&#xD;
               2. Conditions of congenital renal glucosuria&#xD;
&#xD;
               3. Renal allograft&#xD;
&#xD;
               4. Recurrent UTI (urinary tract infection)&#xD;
&#xD;
               5. History of Vesico-ureteral-reflux disease&#xD;
&#xD;
          3. Presence of any medical or psychiatric disorder that may interfere with subject safety&#xD;
             or study conduct&#xD;
&#xD;
          4. Use of metformin, thiazolidinedione or GLP1 agonist within 1 month prior to screening&#xD;
             visit. For those subjects on canagliflozin or other SGLT2 inhibitors, an alternate&#xD;
             study procedure may be utilized as described above&#xD;
&#xD;
          5. Use of any medications (besides insulin or SGLT2 inhibitor) known to effect blood&#xD;
             glucose levels, including oral or other systemic glucocorticoid therapy. Inhaled,&#xD;
             intranasal, or rectal corticosteroid use is allowed as long as not given within 2&#xD;
             weeks of the closed loop admissions. Use of topical glucocorticoids is allowable as&#xD;
             long as affected skin area does not overlap with study device sites&#xD;
&#xD;
          6. History of hypoglycemic seizure within last 3 months&#xD;
&#xD;
          7. History of diabetic ketoacidosis (DKA) requiring medical intervention (ie. emergency&#xD;
             room visit and/or hospitalization) within 1 month prior to the screening visit&#xD;
&#xD;
          8. Allergies or contraindication to the contents of canagliflozin tablets or insulin&#xD;
&#xD;
          9. Volume depleted subjects. Subjects at risk for volume depletion due to co-existing&#xD;
             conditions or concomitant medications, such as loop diuretics who cannot carefully&#xD;
             monitor their volume status should be excluded from the study&#xD;
&#xD;
         10. Female subjects who are pregnant, lactating, or unwilling to be tested for pregnancy&#xD;
&#xD;
         11. Recurrent GU (genitourinary) infections&#xD;
&#xD;
         12. Uncircumcised males secondary to increased risk of development of GU infections&#xD;
&#xD;
         13. History of hypotension, defined as blood pressure (BP) &lt;10th% for age and sex&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neha Patel, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <results_first_submitted>November 1, 2018</results_first_submitted>
  <results_first_submitted_qc>November 1, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 29, 2018</results_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Basal Interruption With or Without Canagliflozin</title>
          <description>Subjects will undergo basal interruption with or without canagliflozin during an overnight stay on the research unit&#xD;
canagliflozin: basal interruption with canagliflozin</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Day 1</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ended Day 1</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Day 2</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ended Day 2</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Basal Interruption With or Without Canagliflozin</title>
          <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit&#xD;
canagliflozin: basal interruption with canagliflozin</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin</title>
        <description>The primary outcome measure for this study will be differences in plasma glucose levels following the interruption of basal subcutaneous infusion of insulin under the two study conditions; i.e., control study during treatment with insulin alone vs. experimental study during treatment with insulin plus canagliflozin or other SGLT2 inhibitor.</description>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Interruption</title>
            <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit&#xD;
basal interruption without canagliflozin: basal interruption</description>
          </group>
          <group group_id="O2">
            <title>Basal Interruption With Canagliflozin</title>
            <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit&#xD;
canagliflozin: basal interruption with canagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Plasma Glucose Levels Following the Interruption of Basal Subcutaneous Infusion of Insulin</title>
          <description>The primary outcome measure for this study will be differences in plasma glucose levels following the interruption of basal subcutaneous infusion of insulin under the two study conditions; i.e., control study during treatment with insulin alone vs. experimental study during treatment with insulin plus canagliflozin or other SGLT2 inhibitor.</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="197" spread="24"/>
                    <measurement group_id="O2" value="99" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal</title>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Interruption</title>
            <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit&#xD;
basal interruption without canagliflozin: basal interruption</description>
          </group>
          <group group_id="O2">
            <title>Basal Interruption With Canagliflozin</title>
            <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit&#xD;
canagliflozin: basal interruption with canagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in BHB (Beta-hydroxybutyrate) Levels Following Interruption of Basal</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="0.2"/>
                    <measurement group_id="O2" value="1.5" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion</title>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Interruption</title>
            <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit&#xD;
basal interruption without canagliflozin: basal interruption</description>
          </group>
          <group group_id="O2">
            <title>Basal Interruption With Canagliflozin</title>
            <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit&#xD;
canagliflozin: basal interruption with canagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Free Fatty Acid Levels Following Interruption of Basal Subcutaneous Insulin Infusion</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.1"/>
                    <measurement group_id="O2" value="0.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion</title>
        <time_frame>20 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Basal Interruption</title>
            <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit&#xD;
basal interruption without canagliflozin: basal interruption</description>
          </group>
          <group group_id="O2">
            <title>Basal Interruption With Canagliflozin</title>
            <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit&#xD;
canagliflozin: basal interruption with canagliflozin</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Glucagon Levels Following the Interruption of the Basal Subcutaneous Insulin Infusion</title>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" spread="5"/>
                    <measurement group_id="O2" value="36" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Basal Interruption</title>
          <description>Subjects will undergo basal interruption without canagliflozin during an overnight stay on the research unit&#xD;
basal interruption without canagliflozin: basal interruption</description>
        </group>
        <group group_id="E2">
          <title>Basal Interruption With Canagliflozin</title>
          <description>Subjects will undergo basal interruption with canagliflozin during an overnight stay on the research unit&#xD;
canagliflozin: basal interruption with canagliflozin</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Vaginal Candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neha S. Patel, DO</name_or_title>
      <organization>Yale Pediatric Diabetes</organization>
      <phone>203-764-6747</phone>
      <email>neha.patel@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

